Serplulimab clinical trials
Also written HLX10.
How each study uses serplulimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the serplulimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 3 Feb 2025 · Hetronifly · EMEA/H/C/006170 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
107 studies that test it; most in 2023 (29)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 13 |
| 2023 | 29 |
| 2024 | 16 |
| 2025 | 14 |
| 2026 | 22 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 81
Shanghai Henlius Biotech (24) · Fudan University (9) · Sun Yat-sen University (5) · Tianjin Medical University Cancer Institute and Hospital (5) · RenJi Hospital (4) · Henan Cancer Hospital (4) · Fujian Cancer Hospital (4) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3)
Often tested with
Tested in the same studies.
Bevacizumab (7) · HMPL-013 (6) · HLX07 (5) · HLX04 (4) · CAPOX Regimen (4) · Paclitaxel (4) · Carboplatin (4) · Etoposide (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 22, 2 in phase 3
Studies that test serplulimab, phase 3 first.
- Dec 2026Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC PatientsPhase 2/3 · Sun Yat-sen University
- Jul 2027A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)Phase 3 · West China Hospital
- Dec 2026Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCPhase 2 · Guangzhou Institute of Respiratory Disease
- Dec 2026Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)Phase 2 · RenJi Hospital
- Dec 2026A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 StudyPhase 2 · Fudan University
- Dec 2026Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal CancerPhase 2 · Zhejiang University
- Dec 2026Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric CancerPhase 2 · Shanghai Zhongshan Hospital
- Dec 2026Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOXPhase 2 · The First Affiliated Hospital with Nanjing Medical University
- Dec 2026Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJCPhase 2 · The First Affiliated Hospital of Zhengzhou University
- Jan 2027Serplulimab Combined With CCRT for LS-SCLC.Phase 2 · Peking Union Medical College Hospital
Studies
Open first, then newest update. How each study uses serplulimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 107
- Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction AdenocarcinomaRecruitingPhase 2National Cancer Center, JapanNCT07699939Written as serplulimab
- Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Beijing Tsinghua Chang Gung HospitalNCT07933471Written as Serplulimab
- A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell CarcinomaNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07904156Written as Serplulimab + Fruquintinib
- Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingPhase 2Fujian Medical University Union HospitalNCT06601309Written as Serplulimab
- NeoCSR-Omics Trial: CAPOX + Serplulimab Before vs. After Short-course RT in LARCRecruitingPhase 2Chongqing University Cancer HospitalNCT07898865Written as Serplulimab
- Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT06860529Written as Serplulimab
- HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric CancerRecruitingPhase 2Shanghai Changzheng HospitalNCT07621484Written as Serplulimab
- A Prospective, Single-center, Phase II Study of Neoadjuvant Serplulimab Plus XELOX and Bevacizumab in Locally Advanced Rectal CancerNot yet recruitingNot applicableTang-Du HospitalNCT07854964Written as Serplulimab
- A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung CancerRecruitingPhase 2People's Hospital of QuzhouNCT07647094Written as Serplulimab, Nab-Paclitaxel, Carboplatin
- Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal CarcinomaRecruitingPhase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07177443Written as Serplulimab
- Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Xijing HospitalNCT07819604Written as Serplulimab
- 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal CancerNot yet recruitingPhase 2Zhejiang UniversityNCT07779694Written as Serplulimab + chemotherapy
- A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingPhase 1/2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT05747729Written as Surufatinib and Serplulimab
- Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07691632Written as Serplulimab + Decitabine + CAPOX (Oxaliplatin + Capecitabine)
- Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCRecruitingPhase 2Guangzhou Institute of Respiratory DiseaseNCT06497530Written as Serplulimab
- A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal CanceNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07622550Written as Serplulimab+Fruquintinib+XELOX
- A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant ChemotherapyRecruitingPhase 2Fudan UniversityNCT07604909Written as Serplulimab
- Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%RecruitingPhase 2Tang-Du HospitalNCT07596121Written as Serplulimab
- A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal CancerRecruitingPhase 3Tao ZhangNCT07113275Written as HLX10
- Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)RecruitingPhase 2RenJi HospitalNCT07283692Written as Serplulimab
See all 107 studies that test serplulimab →
Given beside what is tested · 38 — serplulimab is usual care or a partner of the new treatment
- HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal CancersNot yet recruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07938021Written as Serplulimab
- Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSSNot yet recruitingPhase 3Fudan UniversityNCT07877597Written as Serplulimab
- Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort StudyNot yet recruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07872696Written as Serplulimab
- A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsEnrolling by invitationPhase 1Shanghai Henlius BiotechNCT06115642Written as HLX10
- Efficacy and Safety of Intraoperative Radiotherapy Combined With Serplulimab Plus Chemotherapy Versus Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07870798Written as Serplulimab
- A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07739758Written as Serplulimab
- JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment FailureNot yet recruitingPhase 1/2West China HospitalNCT07175389Written as Serplulimab
- Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 2Shanghai General Hospital, ChinaNCT07733050Written as Serplulimab and Bevacizumab injection
- Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Not yet recruitingPhase 2Beijing Tiantan HospitalNCT07713745Written as Serplulimab
- Luvometinib in Combination With Serplulimab for NF2-Related TumorsNot yet recruitingPhase 1/2Beijing Tiantan HospitalNCT07708285Written as Serplulimab
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNot applicableTang-Du HospitalNCT06128252Written as Serplulimab
- A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCRecruitingPhase 2Shanghai Henlius BiotechNCT07269782Written as Serplulimab
- Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled StudyRecruitingPhase 2Sun Yat-sen UniversityNCT07583511Written as serplulimab
- Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung CancerRecruitingPhase 1Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT07231445Written as Serplulimab
- Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.Not yet recruitingPhase 2Shanghai Henlius BiotechNCT07487519Written as HLX43 DOSE 1 + HLX10
- Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruitingPhase 2Xijing HospitalNCT07466303Written as Serplulimab
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Shanghai Henlius BiotechNCT06857279Written as HLX43 DOSE 2 + HLX10
- Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Zekuan XuNCT06461910Written as Serplulimab
- Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)Not yet recruitingPhase 2Xinhua Hospital, Shanghai Jiao Tong University School of MedicineNCT07381400Written as Serplulimab
- A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal CancerNot yet recruitingPhase 1/2Shanghai Henlius BiotechNCT07358585Written as HLX43 dose 3 + Serplulimab
Showing 20 of 38.
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric CancerOct 22, 2026NCT07621484
Newly registered3
- Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNov 12, 2026NCT07933471
- A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell CarcinomaOct 29, 2026NCT07904156
- NeoCSR-Omics Trial: CAPOX + Serplulimab Before vs. After Short-course RT in LARCOct 27, 2026NCT07898865
Codes
What other systems call serplulimab · ClinicalTrials.gg INT002208
- MeSH (NLM) C000732065serplulimabOne source NLM
- UNII (FDA) S3GQZ2K36VSERPLULIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q130351954serplulimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C156738SerplulimabOne source FDA
- DrugBank DB17451One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732065 | serplulimab | One source NLM |
| UNII (FDA) | S3GQZ2K36V | SERPLULIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q130351954 | serplulimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C156738 | Serplulimab | One source FDA |
| DrugBank | DB17451 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.